Top Markets
Coin of the day
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Pozycja w akcjach #13175
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Cena akcji
$8.46
Ostatnia synchronizacja: 2026-08-28
Kapitalizacja rynkowa
$514.33M
Zmiana (1 dzień)
-2.08%
Zmiana (1 rok)
128.03%
Kraj
US
Handel Kyverna Therapeutics, Inc. (KYTX)

Kategoria

Historia ceny akcji dla Kyverna Therapeutics, Inc. (KYTX)
Najwyższa cena zamknięcia: $8.33 dnia 2026-08-01

Najniższa cena zamknięcia: $28.70 dnia 2024-02-01
Historia cen akcji firmy Kyverna Therapeutics, Inc. od 2024 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) -5.16%
2025 89.56%
2024 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.01 -13.08%
AU
$138.18 473.58%
US
$753.02 6.32%
CH